Cargando…

The conundrum of interleukin-6 blockade in COVID-19

Detalles Bibliográficos
Autores principales:	Campochiaro, Corrado, Dagna, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428300/ https://www.ncbi.nlm.nih.gov/pubmed/32838322 http://dx.doi.org/10.1016/S2665-9913(20)30287-3

Ejemplares similares

Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
por: Tomelleri, Alessandro, et al.
Publicado: (2018)

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
por: Della-Torre, Emanuel, et al.
Publicado: (2020)

The right place for IL-1 inhibition in COVID-19
por: Cavalli, Giulio, et al.
Publicado: (2021)

Myocarditis: An Interleukin-1-Mediated Disease?
por: De Luca, Giacomo, et al.
Publicado: (2018)

Conundrum of IP(6)
por: Vucenik, Ivana
Publicado: (2015)

The course of action for effective anti-cytokine treatment in COVID-19
por: Cavalli, Giulio, et al.
Publicado: (2021)

There is no ‘Conundrum’ of InsP(6)
por: Irvine, Robin F., et al.
Publicado: (2015)

IL-6 blockade for COVID-19: a global scientific call to arms
por: Murthy, Srinivas, et al.
Publicado: (2021)

Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe?
por: Mehta, Puja, et al.
Publicado: (2021)

IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

One year later: The case of tocilizumab in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Predicting extubation success: still a conundrum?
por: Ferguson, Kristin N., et al.
Publicado: (2022)

Cutaneous vasculitis following COVID-19 vaccination
por: Cavalli, Giulio, et al.
Publicado: (2021)

Interleukin-6 inhibitors in non-COVID-19 ARDS: analyzing the past to step into the post-COVID-19 era
por: Gandini, Lucia, et al.
Publicado: (2023)

Predictors of Recurrence for T3a RCC: A Recurring Conundrum
por: Leopold, Zev, et al.
Publicado: (2020)

Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020)

Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement
por: De Luca, Giacomo, et al.
Publicado: (2021)

Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle
por: Farina, Nicola, et al.
Publicado: (2022)

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

A Conundrum
Publicado: (1907)

Replicating research in ecology and evolution: feasibility, incentives, and the cost-benefit conundrum
por: Nakagawa, Shinichi, et al.
Publicado: (2015)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2021)

Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey
por: Tomelleri, Alessandro, et al.
Publicado: (2020)

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
por: Cavalli, Giulio, et al.
Publicado: (2021)

Patent ductus arteriosus, bronchopulmonary dysplasia and pulmonary hypertension—a complex conundrum with many phenotypes?
por: EL-Khuffash, Afif, et al.
Publicado: (2023)

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
por: Cavalli, Giulio, et al.
Publicado: (2020)

A role for interleukin-1 receptor antagonism in severe COVID-19?
por: Tattersall, Rachel S, et al.
Publicado: (2021)

Interleukin-1 Blockade in Acute Myocardial Infarction and Heart Failure: Getting Closer and Closer
por: Toldo, Stefano, et al.
Publicado: (2017)

Preemptive interleukin-6 blockade in patients with COVID-19
por: Guillén, Lucía, et al.
Publicado: (2020)

Rethinking interleukin-6 blockade for treatment of COVID-19
por: Scherger, S., et al.
Publicado: (2020)

Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials
por: Belletti, Alessandro, et al.
Publicado: (2021)

Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?
por: Pickles, Oliver J., et al.
Publicado: (2020)

Face masks and exercise: Novel insights into a contemporary conundrum
por: Vilela, Eduardo M., et al.
Publicado: (2021)

Face masks and exercise: Novel insights into a contemporary conundrum
por: Vilela, Eduardo M., et al.
Publicado: (2021)

Pneumothorax/pneumomediastinum in non-intubated COVID-19 patients: Differences between first and second Italian pandemic wave
por: Palumbo, Diego, et al.
Publicado: (2021)

COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study
por: Ferri, Clodoveo, et al.
Publicado: (2021)

Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis
por: Tomelleri, Alessandro, et al.
Publicado: (2022)

Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure
por: Cavalli, Giulio, et al.
Publicado: (2017)

Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
por: Cavalli, Giulio, et al.
Publicado: (2020)

NKG2A and COVID-19: another brick in the wall
por: Antonioli, Luca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1fs70mc1r6b79j0urcclnh15ck